Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06536452 · ClinicalTrials.gov registry record

Hematopoiesis in MBL and CLL Versus Healthy Age-Matched Control Subjects

A clinical trial of Chronic Lymphocytic Leukemia and Monoclonal B-Cell Lymphocytosis, sponsored by Mayo Clinic.

Recruiting
Registry status
50
Enrollment target
1
Study location

NCT06536452 is a study of Chronic Lymphocytic Leukemia and Monoclonal B-Cell Lymphocytosis that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 50 participants, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06536452, a study of Chronic Lymphocytic Leukemia and Monoclonal B-Cell Lymphocytosis, is actively recruiting participants, sponsored by Mayo Clinic.

RECRUITING
Registry status
50 participants
Enrollment target
1
Study location

Study Summary

This study evaluates hematopoiesis to determine how MBL/CLL affected bone marrow responds to fight off infections in the body.

Interventions

  • OTHER Non-Interventional Study

Study Locations (1)

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2016-11-18
Est. Completion 2026-11-18

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT06536452

The ClinicalTrials.gov registry entry for NCT06536452 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (73% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Non-Interventional Study is the first listed.

NCT06536452 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT06536452 about?

NCT06536452 is a clinical study titled "Hematopoiesis in MBL and CLL Versus Healthy Age-Matched Control Subjects". This study evaluates hematopoiesis to determine how MBL/CLL affected bone marrow responds to fight off infections in the body.

What is the current status of trial NCT06536452?

This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2016-11-18. Estimated completion is 2026-11-18.

What conditions does trial NCT06536452 study?

This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, Monoclonal B-Cell Lymphocytosis.

What interventions are being tested in trial NCT06536452?

The interventions under investigation include: Non-Interventional Study (OTHER).

Who is sponsoring clinical trial NCT06536452?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06536452 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Lymphocytic Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.